NASDAQ · THRD
Healthcare · Biotechnology
$5.38
Down-$0.01 (-0.09%)
Updated Sep 16, 2026, 4:32 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
THRD does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning THRD.
THRD research
Company profile and research snapshot.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 28, 2025 | Stifel | Hold | — |
| Feb 12, 2025 | Morgan Stanley | Equal-Weight | — |
| Feb 11, 2025 | Raymond James | Market Perform | — |
| Aug 9, 2024 | Morgan Stanley | Overweight | — |
| Jun 18, 2024 | Stifel | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Apr 14, 2025
Third Harmonic Bio's board has approved a plan to liquidate and dissolve the company, seeking stockholder approval at the annual meeting in June 2025. The company plans to sell its assets, including the THB335 program, and distribute the remaining cash to shareholders.
Benzinga · Feb 12, 2025
Third Harmonic Bio is halting non-THB335 research, cutting 50% of its workforce, and reviewing strategic options as it prepares to advance THB335 into a Phase 2 trial for chronic spontaneous urticaria.
GlobeNewswire Inc. · Nov 7, 2024
Third Harmonic Bio, a clinical-stage biopharmaceutical company, announced that its CEO and CFO will participate in fireside chats at upcoming healthcare conferences. The company is focused on developing novel treatments for inflammatory diseases.
GlobeNewswire Inc. · May 28, 2024
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning THRD.
No results
No recent SID articles mention THRD.
